The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,029
Antioxidative nanomaterials and biomedical applications
Liu, Y., & Shi, J. (2019) · Nano Today · doi:10.1016/j.nantod.2019.05.008 · Cited by 174
Xu, C., Yan, Y., Tan, J., Yang, D., Jia, X., Wang, L., Xu, Y., Cao, S., & Sun, S. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201808146 · Cited by 172
Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy
Guo, X., Xiao, W., Chen, Z., Zhang, X., Yang, G., & Zhou, S. (2019) · Progress in Materials Science · doi:10.1016/j.pmatsci.2019.100599 · Cited by 171
Smart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review
Kenchegowda, M., Rahamathulla, M., Hani, U., Begum, M. Y., Guruswamy, S., Osmani, R. A. M., Gowrav, M. P., Alshehri, S., Ghoneim, M. M., Alshlowi, A., et al. (2021) · Molecules · doi:10.3390/molecules27010146 · Cited by 181
“Interstitial fluid pressure (IFP) is one obstacle to the efficient deposition of drug-incorporated nanocarriers in cancer cells [15].”
BackgroundBrucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy
Yan, G., Xiao, Q., Zhao, J., Chen, H., Xu, Y., Tan, M., & Peng, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.060 · Cited by 174
Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment
Sonju, J. J., Dahal, A., Singh, S. S., & Jois, S. D. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.055 · Cited by 175
“The effect of MPS on the liposomal drug delivery system can be resolved by employing the surface modification method on liposomes [77].”
MethodUnderstanding and advancement in gold nanoparticle targeted photothermal therapy of cancer
Gupta, N., & Malviya, R. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188532 · Cited by 176
Strategies for the development of metalloimmunotherapies
Sun, X., Zhou, X., Shi, X., Abed, O. A., An, X., Lei, Y. L., & Moon, J. J. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01221-7 · Cited by 199
“Strategies developed for nanomedicines may also aid the delivery of metal ions in patient-acceptable dosage forms with appropriate stability and release profiles 148 , as well as the targeted delivery of ions across physiological barriers to specific tissues and cells 159 .”
Zhang, Z., & Song, S.-C. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.015 · Cited by 175
Shim, M. K., Park, J., Yoon, H. Y., Lee, S., Um, W., Kim, J.-H., Kang, S., Seo, J., Hyun, S., Park, J. H., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.032 · Cited by 169
Recent advances in nanotechnology-based drug delivery systems for the kidney
Oroojalian, F., Charbgoo, F., Hashemi, M., Amani, A., Robati, R. Y., Mokhtarzadeh, A., Ramezani, M., & Hamblin, M. R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.027 · Cited by 170
Xu, X., Deng, G., Sun, Z., Luo, Y., Liu, J., Yu, X., Zhao, Y., Gong, P., Liu, G., Zhang, P., et al. (2021) · Advanced Materials · doi:10.1002/adma.202102322 · Cited by 171
Chiang, M.-R., Hsu, C.-W., Pan, W.-C., Tran, N.-T., Lee, Y.-S., Chiang, W.-H., Liu, Y.-C., Chen, Y.-W., Chiou, S.-H., & Hu, S.-H. (2025) · ACS Nano · doi:10.1021/acsnano.4c09525 · Cited by 174
Recent Advancements of Magnetic Nanomaterials in Cancer Therapy
Mukherjee, S., Liang, L. R., & Omid Veiseh, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020147 · Cited by 176
Dehghani, M., Gulvin, S. M., Flax, J. D., & Gaborski, T. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-66434-7 · Cited by 169
Stimuli‐responsive crosslinked nanomedicine for cancer treatment
Xue, X., Qu, H., & Li, Y. (2022) · Exploration · doi:10.1002/exp.20210134 · Cited by 169
Nanotechnology in combating biofilm: A smart and promising therapeutic strategy
Mohanta, Y. K., Chakrabartty, I., Mishra, A. K., Chopra, H., Mahanta, S., Avula, S. K., Patowary, K., Ahmed, R., Mishra, B., Mohanta, T. K., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1028086 · Cited by 173
“Also, NPs leave the body quickly through the kidneys and stay in the blood for a long time (Blanco et al., 2015; Ramasamy and Lee, 2016).”
BackgroundLeveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Bioinorganic antimicrobial strategies in the resistance era
Regiel-Futyra, A., Dąbrowski, J. M., Mazuryk, O., Śpiewak, K., Kyzioł, A., Pucelik, B., Brindell, M., & Stochel, G. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.005 · Cited by 168
Innovative nano-carriers in anticancer drug delivery-a comprehensive review
Dong, P. W., Rakesh, K. P., Manukumar, H. M. G., Mohammed, Y. H. I., Karthik, C. S., Sumathi, S., Mallu, P., & Qin, H. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.019 · Cited by 166
Dosta, P., Cryer, A. M., Dion, M. Z., Shiraishi, T., Langston, S., Lok, D. P. P., Wang, J., Harrison, S., Hatten, T., Ganno, M. L., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01447-7 · Cited by 179
“45).”
BackgroundFacile Generation of Tumor‐pH‐Labile Linkage‐Bridged Block Copolymers for Chemotherapeutic Delivery
Sun, C., Liu, Y., Du, J., Cao, Z., Xu, C., & Wang, J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201509507 · Cited by 166
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
Li, M., Zou, P., Tyner, K. M., & Lee, S. (2016) · The AAPS Journal · doi:10.1208/s12248-016-0010-3 · Cited by 174
“There are significant differences in EPR effects among different types of tumors as well as between animal tumor models and human tumors (24), which should be considered when describing EPR effects of nanoparticles in a PBPK model.”
BackgroundZhang, Z., Wang, H., Tan, T., Li, J., Wang, Z., & Li, Y. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801840 · Cited by 168
Magnetic nanoparticles: A multifunctional vehicle for modern theranostics
Angelakeris, M. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.02.022 · Cited by 170
Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?
Cui, L., Her, S., Borst, G. R., Bristow, R. G., Jaffray, D. A., & Allen, C. J. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.07.007 · Cited by 169
Fan, W., Lu, N., Shen, Z., Tang, W., Shen, B., Cui, Z., Shan, L., Yáng, Z., Wang, Z., Jacobson, O., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09158-1 · Cited by 164
Khan, S., Mansoor, S., Rafi, Z., Kumari, B., Shoaib, A., Saeed, M., Alshehri, S., Ghoneim, M. M., Rahamathulla, M., Hani, U., et al. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.118008 · Cited by 178
Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours
Wang, Q., Liang, Q., Dou, J., Zhou, H., Zeng, C., Pan, H., Shen, Y., Li, Q., Liu, Y., Leong, D. T., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01498-w · Cited by 167
Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy
Zhu, Y., Li, Q., Wang, C., Hao, Y., Yang, N., Chen, M., Ji, J., Feng, L., & Liu, Z. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00822 · Cited by 163
Host Materials Transformable in Tumor Microenvironment for Homing Theranostics
Yang, P., Luo, Q., Qi, G., Gao, Y., Li, B., Zhang, J., Wang, L., & Wang, H. (2017) · Advanced Materials · doi:10.1002/adma.201605869 · Cited by 164
Zhu, Y., Jia, H., Pan, G., Ulrich, N. W., Chen, Z., & Wu, F. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13672 · Cited by 163
Organic dye assemblies with aggregation‐induced photophysical changes and their bio‐applications
Ji, C., Lai, L., Li, P., Wu, Z., Cheng, W., & Yin, M. (2021) · Aggregate · doi:10.1002/agt2.39 · Cited by 162
Johnsen, K. B., Bak, M., Melander, F., Thomsen, M. S., Burkhart, A., Kempen, P. J., Andresen, T. L., & Moos, T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.005 · Cited by 164
Liu, J., Zhang, R., & Xu, Z. P. (2019) · Small · doi:10.1002/smll.201900262 · Cited by 161
Liu, P., Gao, C., Chen, H., Vong, C. T., Wu, X., Tang, X., Wang, S., & Wang, Y. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.003 · Cited by 168
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications
Akoumianakis, I., Polkinghorne, M., & Antoniades, C. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00718-5 · Cited by 167
Nanogels for intracellular delivery of biotherapeutics
Li, D., van Nostrum, C. F., Mastrobattista, E., Vermonden, T., & Hennink, W. E. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.020 · Cited by 161
Branched and Dendritic Polymer Architectures: Functional Nanomaterials for Therapeutic Delivery
Cook, A. B., & Perrier, S. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201901001 · Cited by 164
Efficient Delivery of Nerve Growth Factors to the Central Nervous System for Neural Regeneration
Xu, D., Wu, D., Qin, M., Nih, L. R., Liu, C., Cao, Z., Ren, J., Chen, X., He, Z., Yu, W., et al. (2019) · Advanced Materials · doi:10.1002/adma.201900727 · Cited by 163
Fluoro‐Photoacoustic Polymeric Renal Reporter for Real‐Time Dual Imaging of Acute Kidney Injury
Cheng, P., Chen, W., Li, S., He, S., Miao, Q., & Pu, K. (2020) · Advanced Materials · doi:10.1002/adma.201908530 · Cited by 162
Huang, J., He, B., Zhang, Z., Li, Y., Kang, M., Wang, Y., Li, K., Wang, D., & Tang, B. Z. (2020) · Advanced Materials · doi:10.1002/adma.202003382 · Cited by 161
Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections
Sánchez, A., Mejía, S. P., & Orozco, J. (2020) · Molecules · doi:10.3390/molecules25163760 · Cited by 165
“Therefore, nanoparticles with discoidal and rod shapes can be designed for targeting vascular endothelium with improved interaction [84,85].”
BackgroundInfluentialOligonucleotide Therapeutics: From Discovery and Development to Patentability
Moumné, L., Marie, A.-C., & Crouvezier, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020260 · Cited by 169
Large‐Scale Synthesis and Medical Applications of Uniform‐Sized Metal Oxide Nanoparticles
Kwon, H. J., Shin, K., Soh, M., Chang, H., Kim, J., Lee, J., Ko, G., Kim, B. H., Kim, D., & Hyeon, T. (2018) · Advanced Materials · doi:10.1002/adma.201704290 · Cited by 163
Chen, M., Liang, X., Gao, C., Zhao, R., Zhang, N., Wang, S., Chen, W., Zhao, B., Wang, J., & Dai, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b03674 · Cited by 159
He, H., Guo, C., Wang, J., Korzun, W. J., Wang, X., Ghosh, S., & Yang, H. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01892 · Cited by 161
Self-Assembled Peptide Drug Delivery Systems
Yang, J., An, H., & Wang, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00707 · Cited by 164
Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine
Sun, T., Kwong, C. H. T., Cheng, G., Wei, J., Yue, L., Zhang, J., Ye, R. D., & Wang, R. (2020) · Theranostics · doi:10.7150/thno.48448 · Cited by 160
“5 in all formulations mainly accumulated in the liver due to the liver’s filtration effects [49].”
BackgroundPaunovska, K., Gil, C. J., Lokugamage, M. P., Sago, C. D., Sato, M., Lando, G. N., Gamboa Castro, M., Bryksin, A. V., & Dahlman, J. E. (2018) · ACS Nano · doi:10.1021/acsnano.8b03640 · Cited by 160
Molecular Engineering of Acoustic Protein Nanostructures
Lakshmanan, A., Farhadi, A., Nety, S. P., Lee‐Gosselin, A., Bourdeau, R. W., Maresca, D., & Shapiro, M. G. (2016) · ACS Nano · doi:10.1021/acsnano.6b03364 · Cited by 159
The spleen in liver cirrhosis: revisiting an old enemy with novel targets
Li, L., Duan, M., Chen, W., Jiang, A., Li, X., Yang, J. J., & Li, Z. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1214-8 · Cited by 167
“An excellent review of the principles of nanoparticle design can be found elsewhere [83].”
BackgroundLayered double hydroxide nanostructures and nanocomposites for biomedical applications
Yan, L., Gonca, S., Zhu, G., Zhang, W., & Chen, X. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01312a · Cited by 161
Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
Jia, R., Teng, L., Gao, L., Su, T., Fu, L., Qiu, Z., & Bi, Y. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s293427 · Cited by 163
Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy
Cheng, Y., Li, L., Hu, P., Yang, Y., Wei, W., Deng, X., Wang, L., Tay, F. R., & Ma, J. (2021) · Advanced Science · doi:10.1002/advs.202100540 · Cited by 163
Design of nanocarriers based on complex biological barriers in vivo for tumor therapy
Liu, J., Li, M., Luo, Z. Y., Dai, L., Guo, X., & Cai, K. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.010 · Cited by 158
Bunker, A., & Róg, T. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.604770 · Cited by 162
Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 160
Agha, A., Waheed, W., Stiharu, I. G., Nerguizian, V., Destgeer, G., Abu‐Nada, E., & Alazzam, A. (2023) · Discover Nano · doi:10.1186/s11671-023-03792-x · Cited by 162
“As a result, there has been tremendous interest over the past decade to engineer NPs for targeted drug delivery [15, 20, 21].”
BackgroundCheng, K., Chen, H., Jenkins, C. H., Zhang, G., Zhao, W., Zhang, Z., Han, F., Fung, J., Yang, M., Jiang, Y., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b05966 · Cited by 156
Nanomaterial-Enabled Cancer Therapy
Quader, S., & Kataoka, K. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.026 · Cited by 159
Liu, Y., Yáng, Z., Huang, X., Yu, G., Wang, S., Zhou, Z., Shen, Z., Fan, W., Liu, Y., Davisson, M., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b02980 · Cited by 156
Advances in Lipid and Metal Nanoparticles for Antimicrobial Peptide Delivery
Makowski, M., Silva, Í. C., do Amaral, C. P., Gonçalves, S., & Santos, N. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110588 · Cited by 158
“Depending on the NP shape, size and surface chemistry, the binding of a functionalized nanoparticle can promote or enhance specificity to target cells or cell surface molecules [37].”
BackgroundKorangath, P. C., Barnett, J. D., Sharma, A., Henderson, E. T., Stewart, J., Yu, S.-H., Kandala, S. K., Yang, C.-T., Caserto, J. S., Hedayati, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay1601 · Cited by 157
Rahman, M. M., Islam, M. R., Akash, S., Harun-Or-Rashid, M., Ray, T. K., Rahaman, M. S., Islam, M., Anika, F., Hosain, M. K., Aovi, F. I., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113305 · Cited by 162
RetractedAhmad, A., Imran, M., & Sharma, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112463 · Cited by 170
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles
Kang, H., Mintri, S., Menon, A. V., Lee, H. Y., Choi, H. S., & Kim, J. (2015) · Nanoscale · doi:10.1039/c5nr05264e · Cited by 156
Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery
Sun, Y., Ye, X., Cai, M., Liu, X., Xiao, J., Zhang, C., Wang, Y., Yang, L., Liu, J., Li, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07828 · Cited by 157
“cytotoxicity or conjugation with functional ligands may offer advantages over conventional nanoparticle delivery systems.(19) Unlike traditional lipid-based nanoparticles, polyurethane (PU) nanomicelles encapsulate small nucleic acids via electrostatic interactions, and Page 4 of 29”
BackgroundChen, D., Ganesh, S., Wang, W., & Amiji, M. M. (2019) · Nanoscale · doi:10.1039/c8nr09855g · Cited by 158
Immunomodulating Nanomedicine for Cancer Therapy
Liu, Z., Jiang, W., Nam, J., Moon, J. J., & Kim, B. Y. S. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02340 · Cited by 154
Synthetic and living micropropellers for convection-enhanced nanoparticle transport
Schuerle, S., Soleimany, A. P., Yeh, T., Anand, G. M., Häberli, M., Fleming, H. E., Mirkhani, N., Qiu, F., Hauert, S., Wang, X., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4803 · Cited by 154
“While they are designed to alter the pharmacokinetics and biodistribution of their associated drugs, physiological barriers to NP transport often impede their successful accumulation at diseased sites, limiting their therapeutic effect in ailments ranging from cancer to inflammation (2, 3).”
BackgroundWang, J., Zhu, M., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113974 · Cited by 153
Lithography-based methods to manufacture biomaterials at small scales
Tran, K. T. M., & Nguyen, T. D. (2016) · Journal of Science Advanced Materials and Devices · doi:10.1016/j.jsamd.2016.12.001 · Cited by 161
Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys
Tietjen, G. T., Hosgood, S. A., DiRito, J. R., Cui, J., Deep, D., Song, E., Kraehling, J. R., Piotrowski-Daspit, A. S., Kirkiles-Smith, N. C., Al‐Lamki, R. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6764 · Cited by 153
Sung, S., Su, Y., Cheng, W., Hu, P.-F., Chiang, C., Chen, W., & Hu, S. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03249 · Cited by 154
Zhuang, J., Duan, Y., Zhang, Q., Gao, W., Li, S., Fang, R. H., & Zhang, L. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01654 · Cited by 153
Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview
Mosleh-Shirazi, S., Abbasi, M., Moaddeli, M. R., Vaez, A., Shafiee, M., Kasaee, S. R., Amani, A. M., & Hatam, S. (2022) · Nanotheranostics · doi:10.7150/ntno.74613 · Cited by 165
“If, on the other hand, a non-biodegradable material is used, it must have been proved to be harmless at required levels or to be free from the source material [47-49].”
BackgroundPrecision drug delivery to the central nervous system using engineered nanoparticles
Gao, J., Xia, Z. J., Gunasekar, S., Jiang, C., Karp, J. M., & Joshi, N. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00695-w · Cited by 163
“the size, surface charge and charge density of NPs have proven effective in tuning their pharmacokinetic properties 58,74,141 .”
Hou, B., Zhou, L., Wang, H., Saeed, M., Wang, D., Xu, Z., Li, Y., & Yu, H. (2020) · Advanced Materials · doi:10.1002/adma.201907210 · Cited by 153
Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies
Wang, K., Kievit, F. M., & Zhang, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.016 · Cited by 157
Tannic Acid-Mediated Surface Functionalization of Polymeric Nanoparticles
Abouelmagd, S. A., Meng, F., Kim, B.-K., Hyun, H., & Yeo, Y. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00497 · Cited by 156
Alves, C. G., Lima‐Sousa, R., de Melo‐Diogo, D., Louro, R. O., & Correia, I. J. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.03.020 · Cited by 152
Li, L., Guo, J., Wang, Y., Xiong, X., Tao, H., Li, J., Jia, Y., Hu, H., & Zhang, J. (2018) · Advanced Science · doi:10.1002/advs.201800781 · Cited by 150
Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
Entzian, K., & Aigner, A. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081135 · Cited by 156
“If the charge of nanoparticles is neutral or slightly negative, the circulation half-life in the blood stream is considerably increased compared with their cationic counterparts [88].”
BackgroundStrategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 160
“88).”
Bioconjugated Nanoparticles for Biosensing, in Vivo Imaging, and Medical Diagnostics
Kairdolf, B. A., Qian, X., & Nie, S. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04873 · Cited by 158
Niu, Y., Zhu, J., Li, Y., Shi, H., Gong, Y., Li, R., Huo, Q., Ma, T., & Liu, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.012 · Cited by 149
“One of the commonly accepted explanation for the failure of solid tumor treatment is the inefficient tumor penetration of nanodrugs and the high heterogeneity of solid tumors [3].”
Nanomedicines for Cancer Therapy: Current status, Challenges and Future Prospects
Bor, G., Azmi, I. D. M., & Yaghmur, A. (2019) · Therapeutic Delivery · doi:10.4155/tde-2018-0062 · Cited by 153
2D Layered Double Hydroxide Nanoparticles: Recent Progress toward Preclinical/Clinical Nanomedicine
Cao, Z., Li, B., Sun, L., Li, L., Xu, Z. P., & Gu, Z. (2019) · Small Methods · doi:10.1002/smtd.201900343 · Cited by 151
Zhao, Z., Ukidve, A., Gao, Y., Kim, J., & Mitragotri, S. (2019) · Science Advances · doi:10.1126/sciadv.aax9250 · Cited by 152
Hebner, T. S., & Maurer‐Jones, M. A. (2020) · Environmental Science Processes & Impacts · doi:10.1039/c9em00475k · Cited by 160
Lyu, Z., Ding, L., Tintaru, A., & Peng, L. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00589 · Cited by 152
Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials
Lu, J., Gao, X., Wang, S., He, Y., Ma, X., Zhang, T., & Liu, X. (2023) · Exploration · doi:10.1002/exp.20220045 · Cited by 155
Machine Learning and Artificial Intelligence in Nanomedicine
Chou, W., Canchola, A., Zhang, F., & Lin, Z. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70027 · Cited by 169
“Despite these advances, however, many nanomedicine candidates fail to achieve successful clinical translation (Blanco et al. 2015; Chen et al. 2023; Shi et al. 2017; Wilhelm et al. 2016).”
Repenko, T., Rix, A., Ludwanowski, S., Go, D., Kiessling, F. M., Lederle, W., & Kuehne, A. J. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00545-0 · Cited by 158
Yao, C., Li, Y., Wang, Z., Song, C., Hu, X., & Liu, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b08285 · Cited by 149
Microneedle-based drug delivery: materials of construction
Bhatnagar, S., Gadeela, P. R., Thathireddy, P., & Venuganti, V. V. K. (2019) · Journal of Chemical Sciences · doi:10.1007/s12039-019-1666-x · Cited by 151
“For example, skin does not allow most molecules to permeate to deeper dermal layers.(1) The needle and the syringe have been developed to overcome these barriers and deliver therapeutics directly to the affected areas or to the blood.”
BackgroundmRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 158
Autocatalytic Morphology Transformation Platform for Targeted Drug Accumulation
Cheng, D., Wang, D., Gao, Y., Wang, L., Qiao, Z., & Wang, H. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13512 · Cited by 146
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
